Metallic radionuclide-labeled tetrameric 2,6-diisopropylphenyl azides for cancer treatment.
Chem Commun (Camb)
; 60(24): 3291-3294, 2024 Mar 19.
Article
em En
| MEDLINE
| ID: mdl-38421438
ABSTRACT
This study proposes a new method for radionuclide therapy that involves the use of oligomeric 2,6-diisopropylphenyl azides and a chelator to form stable complexes with metallic radionuclides. The technique works by taking advantage of the endogenous acrolein produced by cancer cells. The azides react with the acrolein to give a diazo derivative that immediately attaches to the nearest organelle, effectively anchoring the radionuclide within the tumor. Preliminary in vivo experiments were conducted on a human lung carcinoma xenograft model, demonstrating the feasibility of this approach for cancer treatment.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Azidas
/
Neoplasias
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article